Who
Stephen L. Sabba
Director
Company insider
Files Form 4 as: Director, Ligand Pharmaceuticals; Director, Novelion Therapeutics.
In numbers
- Trades disclosed
- 109
- Buys
- 3
- Sells
- 11
- Bought
- $109K
- Sold
- $8.0M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 4 Aug 2008
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $142K2,145 at $66.13 | filing |
| 16 Jun 2026filed 18 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $545K2,145 at $254.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,145 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,145 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $142K2,145 at $66.13 | filing |
| 16 Jun 2026filed 18 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $545K2,145 at $254.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $208K1,000 at $207.87 | filing |
| 23 Mar 2026filed 25 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $208K1,000 at $207.87 | filing |
| 3 Mar 2026filed 5 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $141K2,034 at $69.51 | filing |
| 3 Mar 2026filed 5 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $410K2,034 at $201.50 | filing |
| 3 Mar 2026filed 5 Mar 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,034 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,034 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $141K2,034 at $69.51 | filing |
| 3 Mar 2026filed 5 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $410K2,034 at $201.50 | filing |
| 6 Jun 2025filed 10 Jun 2025 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,783 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,209 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.